---
figid: PMC10413047__IJMM-52-2-05271-g02
pmcid: PMC10413047
image_filename: PMC10413047__IJMM-52-2-05271-g02.jpg
figure_link: /pmc/articles/PMC10413047/figure/F3/
number: Figure 3
figure_title: Mechanisms of CASC9 and lncRNA UCA1 in drug resistance in NSCLC.
caption: Mechanisms of CASC9 and lncRNA UCA1 in drug resistance in NSCLC. (A) CASC9
  suppresses the tumor suppressor DUSP1 by recruiting histone methyltransferase EZH2
  and increasing the resistance to gefitinib. (B) LncRNA UCA1 acts as an endogenous
  competitive RNA that can bind with miR-143 to regulate the expression of FOSL2.
  In addition, lncRNA UCA1 increases resistance to cisplatin through the UCA1/miR-495/NRF2
  signaling pathway. CASC9, candidate tumor susceptibility gene 9; lncRNA, long non-coding
  RNA; UCA1, lncRNA urothelial carcinoma-associated; NSCLC, non-small cell lung cancer;
  DUSP1, dual specificity phosphatase 1; miR, microRNA; EZH2, zeste homolog 2
article_title: Long non-coding RNAs as potential therapeutic targets in non-small
  cell lung cancer (Review)
citation: Peiyu Tang, et al. Int J Mol Med. 2023 Aug;52(2).
year: '2023'
pub_date: 2023-8-
epub_date: 2023-6-20
doi: 10.3892/ijmm.2023.5271
journal_title: International Journal of Molecular Medicine
journa_nlm_ta: Int J Mol Med
publisher_name: D.A. Spandidos
keywords:
- lncRNA
- NSCLC
- therapeutic targets
- biomarkers
- drug resistance
---
